Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-02-26
2009-08-11
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S247000, C514S279000, C514S299000, C514S576000, C514S577000, C514S588000, C514S611000, C514S740000, C514S741000, C514S743000, C544S283000, C544S284000, C544S293000
Reexamination Certificate
active
07572798
ABSTRACT:
The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.
REFERENCES:
Reilly, R.M. et al. J. Nucl. Med. 41(3): 429-438, 2000.
Matheson, S. and B. J. Jean-Claude, Proceedings of the American Association for Cancer Research, 41: 423-424, Mar. 2000.
Brahimi, F. et al., Journal of Pharmacology and Experimental Therapeutics, 303(1): 238-246, 2002.
Sinha et al., 1995; Sherwood et al., 1999; Kondapaka and Reddy, 1996; Alaoui-Jamali et al., 1997; Tsai et al., 1993.
Carroll et al., 1997; Deininger et al., 1997; Levitzki and Gazit, 1999.
Xie et al., 1999; Turner et al., 1996; Modjtahedi and Dean, 1998; Moyer et al., 1997.
Levitzki and Gazit, 1999; Rewcastle et al., 1997; Lanzi et al., 1997; Moyer et al., 1997; Rewcastle et al., 1995; Rewcastle et al., 1988.
Smaill et al., 1999.
Moyer, J.D., Barbacci, E.G., Iwata, K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M.J., Moyer, M.J., Neveu, M., Pollak, V.A. Pustilnik, L.R., Reynolds, M.M., Sloan, D., Teleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57: 4838-4848, 1997.
Rewcastle, G.W., Denny, W.A. Bridges, A.J., Hairong, Z., Cody, D.R., McMichael, A., and Fry, D.W. Tyrosine kinase inhibitor. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 38: 3482-3487, 1995.
Rewcastle, G.W., Murray, D.K., Elliott, W.L., Fry, D.W., Howard, C.T., Nelson, J.M., Roberts, B.J., Vincent, P.W., Showalter, H.D., Winters, R.T., and Denny, W.A. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 41: 742-751, 1998.
Caliaro, M.J., Vitaux, P., Lafon, C., Lochon, I., Nehme, A., Valette, A., Canal, P., Bugat, R., and Jozan, S. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br. J. Cancer, 75: 333-340, 1997.
Modjtahedi, H. and Dean, C. The receptor for EGF and its ligands: expression, prognostic value and target for tumour therapy. Int. J. Oncol. 4: 277-296, 1998.
Fry, D.W. (1999): Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82: 207-218.; Smalll et all., 2000.
Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. (2000): Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063.
Rewcastle et al., 1997; Rewcastle et al., 1995.
Rewcastle et al., 1997; Rewcastle et al., 1998; Rewcastle et al., 1995.
Rewcastle, G.W., Bridges, A., Fry, D.W., Rubin, R.R., and Denny, W.A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimidino[5,4d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 40: 1820-1826, 1997.
Rewcastle et al., 1995.
Walker, M.D. Nitrosoureas in central nervous system tumors. Cancer Chemother. Rep. 4: 21-26, 1973.
Walker M.D. and Hurwitz, B.S. BCNU (1,3-bis(2-nitrosourea; NSC-409962) in the treatment of malignant brain tumor—a preliminary report. Cancer Chemother. Rep. 54:273-281, 1970.
Wilson, C.B., Boldrey, E.B., and Enot, K.J. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother. Rep. 54: 273-281, 1970.
Yarosh, D.B., Hurst-Calderone, S., Babich, M.A., and Day, R.S. Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base. Cancer Res. 46: 1663-1668, 1986.
Gibson, N.W., Hartley, J.A., LaFrance, R.J., and Vaughan, K. Differential cytotoxicity and DNA-damage effects produced in human cells of the Mer+ and Mer- phenotypes by a series of 1-aryl-3-alkyltriazenes. Cancer Res. 46: 4999-5003, 1986.
Pegg et al., 1995; Tisdale, 1987; Bodell et al., 1985; Baer et al., 1993.
Ching et al., 1993b; Moyer et al., 1997b.
Tisdale, 1987; Mitchel and Dolan, 1993; Lee et al., 1991; Chen et al., 1993.
Matheson, S.L.M.; McNamee, J.P.; Jean-Claude, B.J. (2001): Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharm Exp Ther 296: 832-840.
Baig, G.U., Stevens, M.F.G. (1987): Antitumor imidazotetrazines. Part 12. Reactions of mitozolomide and its 3-alkyl congeners with oxygen, nitrogen, halogen, and carbon nucleophiles. J Chem Soc Perkin Trans 1, 1665-667. Cameron, L.M.; LaFrance, R.J.; Hemens, C.M.; Vaughan, K.; Rajaraman, R.; Chubb, D.C.; Goddard, P.M.;(1985): Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potentialprodrugs for the active metabolites of the anti-tumour triazene, DTIC. Anti-Cancer Drug Des 1: 27-36.
Stevens, M.F.G.; Hickman, J.A.; Stone, R.; Gibson, N.W.; Baig, G.U.; Lunt, E., Newton, C.G.; (1984): Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)midazo[5,1,-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent.J Med. Chem27: 196-201. Stevens, M.F.G.; Hickman, J.A.; Langdon, S.P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N.W.; Slack, J.A.; (1987): Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852.
Tsai, C.M., Levitzki, A., Wu, L.H., Chang, K.T., Cheng, C., Gazit, A., and Perng, R.P. Enhancement of chemosensitivity by tyrphostin AG825 in High-p185 expressing non-small cell lung cancer cells. Cancer Res. 56: 1068-1074, 1996.
Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M.J.; Moyer, M.P.; (1997): Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848.; Vincent, P.W.; Bridges, A.J.; Dykes, D.J.; Fry, D.W.; Leopold, W.R.; Patmore, S.J.; Roberts, B.J.; Rose, S.; Sherwood, V.; Zhou, H. (2000): Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chem Pharmacol 45: 231-238.
Singh et al., 1994.
McNamee, J.P.; Mclean, J.R.; Ferrarotto, C.L.; Bellier, P.V. (2000): Comet assay: rapid processing of multiple samples. Mutation Res 466: 63-69.
Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. (1990): New colorimetric cytotoxicity assay for anti-cancer drug screening.JNatl Cancer Inst 82: 1107-1112.
Cameron et al., 1985; Manning, H.W.; Cameron, L.M.; LaFrance, R.J.; Vaughan, K.; Rajaman, R. (1985): Triazene metabolism. V. Chemical and biological properties of N,N-bis-[1-aryl-3-methyltriazen-3-yl)-methyl]-met
Dudouit Fabienne
Jean-Claude Bertrand J.
Matheson Stephanie
Fulbright & Jaworski L.L.P.
Harris Alana M.
Holleran Anne L
McGill University
LandOfFree
Combi-molecules having signal transduction inhibitory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combi-molecules having signal transduction inhibitory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combi-molecules having signal transduction inhibitory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098474